Home » Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial
Pfizer’s Sutent Meets Primary Endpoint in Pivotal Trial
Pfizer has unveiled positive results from a Phase 3 trial evaluating Sutent as adjuvant therapy in patients at high risk of recurrent renal cell carcinoma after surgery.
The tyrosine kinase inhibitor reached its primary endpoint of prolonging disease-free survival in the adjuvant setting compared to placebo.
The treatment was approved in 2006 in the U.S. for the treatment of advanced RCC.
Upcoming Events
-
07May
-
14May
-
30May